Clinical Trial Update: A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating axitinib or bevacizumab in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer; the trial is completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Axitinib (Axitinib)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Pfizer | Conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2012-05-22